Skip to content
NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Pfizer Inc. PFE

19 fiscal years on record · USD · FY2025 reported · SEC filings only
15 YEARS OF DIVIDEND GROWTH
$62.6B
▼ 1.6% YoY
$7.8B
▼ 3.2% YoY
$9.1B
▼ 7.7% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Pfizer discovers, develops, manufactures, markets, sells and distributes biopharmaceutical products worldwide. It manages its commercial operations through a global structure consisting of three operating segments: Biopharma, PC1 and Pfizer Ignite. Biopharma is the only reportable segment. PC1 is the company's contract development and manufacturing organization and a supplier of specialty active pharmaceutical ingredients. Pfizer Ignite provides strategic guidance and end-to-end R&D services to select biotech companies, and in 2025 Pfizer made the decision to discontinue the offering and is winding down the business. The company was incorporated under the laws of the State of Delaware on June 2, 1942.

Written from the business description in PFIZER INC's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 62.6B
Revenue, FY2025 · full 19-year series below
Revenue $B Net income $B
FY2025 · Revenue 62.6 · Net income 7.8
50B100B
2007201020132016201920222025
Compound annual growth
−14.8%
+8.5%
+2.5%
−0.3%
−37.2%
−3.2%
+1.1%
−0.4%
−37.1%
−3.6%
+2.1%
+1.9%
+2.2%
+2.4%
+4.4%
+6.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +8.5% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

12 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 12.0% · Net 12.5%
20%40%
200720162025
ROE
FY2025 · ROE 8.9%
10%20%30%
200720162025
Three returns, three denominators.
Return on capital employedNot available: we don't have a clean operating profit figure for this period.

Each USD of equity produced 9 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 9.1
15B30B
200720162025
Net buybacks $B Dividends $B
FY2024 · Dividends · · Net buybacks 0.0
10B20B
2007201020132016201920222024

Total assetsUSD 208.2B
EquityUSD 86.5B
CashUSD 1.1B
Gross debtUSD 64.6B
Net debtUSD 63.5B
Current ratio1.16×

Net debt stands at 73% of equity.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
PFE, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B62.663.659.6101.281.341.740.940.852.552.848.949.651.654.761.065.249.348.348.4
Operating income $B7.58.01.134.724.37.011.33.612.38.49.012.215.711.211.59.510.7◌◌
EBITDA $B14.115.07.339.829.511.717.110.018.614.114.117.822.018.620.217.915.4◌◌
Income tax $B−0.3−0.0−1.13.31.90.40.6−0.3−9.01.12.03.14.32.23.61.22.11.61.0
Net income $B7.88.02.131.422.09.216.011.221.37.27.09.122.014.610.08.38.68.18.1
Free cash flow $B9.19.84.826.029.912.210.513.814.814.413.315.916.515.418.69.915.416.511.5
EPS, diluted $1.361.410.375.473.851.632.821.873.521.171.111.423.191.941.271.021.231.201.17
Dividend / sh $1.721.691.651.611.571.531.461.381.301.221.121.040.960.880.800.72◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %8.99.12.336.331.314.525.316.632.611.610.212.427.917.811.89.311.713.212.5

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 74 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Two checks were skipped: the balance sheet is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image